Giuseppe
Emeritus
[Source: Eurosurveillance, full text: (LINK). Abstract, edited.]
A Sandgren (
)<SUP>1</SUP>, V Hollo<SUP>1</SUP>, E Huitric<SUP>1</SUP>, C K?dm?n<SUP>1</SUP>
Citation style for this article: Sandgren A, Hollo V, Huitric E, K?dm?n C. Epidemiology of tuberculosis in the EU/EEA in 2010 ? monitoring the progress towards tuberculosis elimination. Euro Surveill. 2012;17(12)
ii=20124. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20124
Date of submission: 22 February 2012 <HR>The 2012 combined tuberculosis (TB) surveillance and monitoring report for the European Union and European Economic Area identifies a mean annual decline in TB notification rate by 4.4% from 2006 to 2010. Culture confirmation for new pulmonary cases and drug susceptibility testing have increased to 65.6% and 70.8%, but remain under their targets of 80% and 100%, respectively. Reporting of treatment outcome and co-infection with human immunodeficiency virus also remain suboptimal. Strengthened control practices are needed to allow progress towards TB elimination.
- -----
Eurosurveillance, Volume 17, Issue 12, 22 March 2012
Rapid communications
Epidemiology of tuberculosis in the EU/EEA in 2010 ? monitoring the progress towards tuberculosis elimination
Rapid communications
Epidemiology of tuberculosis in the EU/EEA in 2010 ? monitoring the progress towards tuberculosis elimination
A Sandgren (
- European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Citation style for this article: Sandgren A, Hollo V, Huitric E, K?dm?n C. Epidemiology of tuberculosis in the EU/EEA in 2010 ? monitoring the progress towards tuberculosis elimination. Euro Surveill. 2012;17(12)
ii=20124. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20124 Date of submission: 22 February 2012 <HR>The 2012 combined tuberculosis (TB) surveillance and monitoring report for the European Union and European Economic Area identifies a mean annual decline in TB notification rate by 4.4% from 2006 to 2010. Culture confirmation for new pulmonary cases and drug susceptibility testing have increased to 65.6% and 70.8%, but remain under their targets of 80% and 100%, respectively. Reporting of treatment outcome and co-infection with human immunodeficiency virus also remain suboptimal. Strengthened control practices are needed to allow progress towards TB elimination.